Anti-IgE-emerging opportunities for Omalizumab

Expert Opinion on Biological Therapy

Volumn 13, Issue 5, 2013, Pages 765-777

  Babu, K Suresh ^a   Polosa, Riccardo ^b   Morjaria, Jaymin B ^c  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CATANIA   (Italy)

^c UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Allergic rhinitis; Anti IgE; Dermatitis; Food allergy; Immunotherapy; Omalizumab; Urticaria

Indexed keywords

IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB; PLACEBO;

ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ALLERGIC REACTION; ALLERGY; ANAPHYLAXIS; ASTHMA; ATOPIC DERMATITIS; ATOPIC KERATOCONJUNCTIVITIS; CD4+ T LYMPHOCYTE; CHRONIC URTICARIA; DRUG EFFICACY; DRUG SAFETY; ECZEMA; EOSINOPHILIC ESOPHAGITIS; EOSINOPHILIC GASTROENTERITIS; FOOD ALLERGY; HAY FEVER; HEVEA BRASILIENSIS; HUMAN; JAPANESE CEDAR; MASTOCYTOSIS; NOSE POLYP; OUTCOME ASSESSMENT; PERENNIAL RHINITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN MANIFESTATION; SKIN TEST; SYSTEMIC MASTOCYTOSIS;

ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; DERMATITIS, CONTACT; FOOD HYPERSENSITIVITY; GASTROINTESTINAL DISEASES; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOTHERAPY; RHINITIS, ALLERGIC, PERENNIAL; RHINITIS, ALLERGIC, SEASONAL; WASP VENOMS;

ARACHIS HYPOGAEA;

EID: 84876047977     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.782391     Document Type: Review

References (122)

1. Prausnitz C, Kustner H. Studien uber die uberempfindlichkeit. Zentralblat fur Bakteriologie 1921;86:160-9
2. Johansson SG, Bennich H, Wide L. A new class of immunoglobulin in human serum. Immunology 1968;14(2):265-72
3. Morjaria JB, Gnanakumaran G, Babu KS. Anti-IgE in allergic asthma and rhinitis: an update. Expert Opin Biol Ther 2007;7(11):1739-47
4. Parravicini V, Gadina M, Kovarova M, et al. Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. Nat Immunol 2002;3(8):741-8
5. Bonnefoy JY, Lecoanet-Henchoz S, Gauchat JF, et al. Structure and functions of CD23. Int Rev Immunol 1997;16(1-2):113-28
6. Poole JA, Meng J, Reff M, et al. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J Allergy Clin Immunol 2005;116(4):780-8
7. Van Cauwenberge PB. Nasal sensitization. Allergy 1997;52(33 Suppl):7-9
8. de Vries JE, Carballido JM, Aversa G. Receptors and cytokines involved in allergic TH2 cell responses. J Allergy Clin Immunol 1999;103(5 Pt 2):S492-6
9. Gauchat JF, Lebman DA, Coffman RL, et al. Structure and expression of germline epsilon transcripts in human B cells induced by interleukin 4 to switch to IgE production. J Exp Med 1990;172(2):463-73
10. Presta L, Shields R, O'Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 1994;269(42):26368-73
11. Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol 1993;151(5):2623-32
12. Omalizumab, Xolair, label information. Available from: www.fda.gov/cder/foi/ label/2003/omalgen062003LB.pdf
13. Fox JA, Hotaling TE, Struble C, et al. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 1996;279(2):1000-8
14. Liu J, Lester P, Builder S, et al. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 1995;34(33):10474-82
15. Ghetie V, Hubbard JG, Kim JK, et al. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 1996;26(3):690-6
16. Mariani G, Strober W. Immunoglobulin metabolism. In: Metzger H, editor. Receptors and the action of antibodies. American Society of Microbiology, Washington DC; 1990. p. 94-177
17. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2007
18. Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60(3):302-8
19. Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34(4):632-8
20. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60(3):309-16
21. Bousquet J, van Cauwenbage P, Khaltaey N. Allergic rhinitis and its impact on asthma (ARIA) workshop report. J Allergy Clin Immunol 2001;108(Suppl):S147-334
22. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21(1):77-83
23. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000;106(2):253-9
24. Casale TB, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001;286(23):2956-67
25. Nayak A, Casale T, Miller SD, et al. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc 2003;24(5):323-9
26. Okubo K, Ogino S, Nagakura T, et al. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int 2006;55(4):379-86
27. Ogino S, Nagakura T, Okubo K, et al. Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated. Int Arch Allergy Immunol 2009;149(3):239-45
28. Nagakura T, Ogino S, Okubo K, et al. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Clin Exp Allergy 2008;38(2):329-37
29. Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 2003;91(2):160-7
30. Bachert C, Vignola AM, Gevaert P, et al. Allergic rhinitis, rhinosinusitis, and asthma: one airway disease. Immunol Allergy Clin North Am 2004;24(1):19-43
31. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59(7):709-17
32. Corren J, Shapiro G, Reimann J, et al. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. J Allergy Clin Immunol 2008;121(2):506-11
33. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010(8):CD001186
34. Holgate S, Smith N, Massanari M, et al. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 2009;64(12):1728-36
35. Eckman JA, Sterba PM, Kelly D, et al. Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge. J Allergy Clin Immunol 2010;125(4):889-95 e7
36. Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109(2):274-80
37. Rolinck-Werninghaus C, Hamelmann E, Keil T, et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy 2004;59(9):973-9
38. Kopp MV, Stenglein S, Kamin W, et al. Omalizumab (Xolair) in children with seasonal allergic rhinitis: leukotriene release as a potential in vitro parameter to monitor therapeutic effects. Pediatr Allergy Immunol 2007;18(6):523-7
39. Kopp MV, Brauburger J, Riedinger F, et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol 2002;110(5):728-35
40. Kamin W, Kopp MV, Erdnuess F, et al. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol 2010;21(1 Pt 2):e160-5
41. Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009;39(2):271-9
42. Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010;125(2):383-9
43. Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006;117(1):134-40
44. Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008;63(3):376-8
45. Schulze J, Rose M, Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 2007;62(8):963-4
46. Galera C, Soohun N, Zankar N, et al. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol 2009;19(3):225-9
47. Leung DY, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 2001;44(1 Suppl):S1-S12
48. Lane JE, Cheyney JM, Lane TN, et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006;54(1):68-72
49. Park SY, Choi MR, Na JI, et al. Recalcitrant atopic dermatitis treated with omalizumab. Ann Dermatol 2010;22(3):349-52
50. Amrol D. Anti-immunoglobulin e in the treatment of refractory atopic dermatitis. South Med J 2010;103(6):554-8
51. Ramirez del Pozo ME, Contreras Contreras E, Lopez Tiro J, et al. Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema. J Investig Allergol Clin Immunol 2011;21(5):416-17
52. Fernandez-Anton Martinez MC, Leis-Dosil V, Alfageme-Roldan F, et al. Omalizumab for the treatment of atopic dermatitis. Actas Dermosifiliogr 2012;103(7):624-8
53. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005;53(2):338-40
54. Sheinkopf LE, Rafi AW, Do LT, et al. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 2008;29(5):530-7
55. Vigo PG, Girgis KR, Pfuetze BL, et al. Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 2006;55(1):168-70
56. Belloni B, Ziai M, Lim A, et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007;120(5):1223-5
57. Velling P, Skowasch D, Pabst S, et al. Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy. Eur J Med Res 2011;16(9):407-10
58. Available from: clinicaltrials.gov [Last accessed September 2011]
59. Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007;99(2):190-3
60. Vestergaard C, Deleuran M. Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab. Acta Derm Venereol 2010;90(4):443-4
61. Metz M, Bergmann P, Zuberbier T, et al. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy 2008;63(2):247-9
62. Iemoli E, Piconi S, Fusi A, et al. Immunological effects of omalizumab in chronic urticaria: a case report. J Investig Allergol Clin Immunol 2010;20(3):252-4
63. Magerl M, Staubach P, Altrichter S, et al. Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. J Allergy Clin Immunol 2010;126(3):665-6
64. Ivyanskiy I, Sand C, Francis ST. Omalizumab for chronic urticaria: a case series and overview of the literature. Case Rep Dermatol 2012;4(1):19-26
65. Groffik A, Mitzel-Kaoukhov H, Magerl M, et al. Omalizumab - an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy 2011;66(2):303-5
66. Sabroe RA. Failure of omalizumab in cholinergic urticaria. Clin Exp Dermatol 2010;35(4):e127-9
67. Kaplan AP, Joseph K, Maykut RJ, et al. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008;122(3):569-73
68. Maurer M, Altrichter S, Bieber T, et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011;128(1):202-9 e5
69. Saini S, Rosen KE, Hsieh HJ, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011;128(3):567-73; e1
70. Boyce JA. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol 2006;117(6):1415-18
71. Guzelbey O, Ardelean E, Magerl M, et al. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy 2008;63(11):1563-5
72. Waibel KH, Reese DA, Hamilton RG, et al. Partial improvement of solar urticaria after omalizumab. J Allergy Clin Immunol 2010;125(2):490-1
73. Duchini G, Baumler W, Bircher AJ, et al. Failure of omalizumab (Xolair(R)) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light. Photodermatol Photoimmunol Photomed 2011;27(6):336-7
74. Metz M, Altrichter S, Ardelean E, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol 2011;154(2):177-80
75. Fairley JA, Baum CL, Brandt DS, et al. Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 2009;123(3):704-5
76. Carter MC, Robyn JA, Bressler PB, et al. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007;119(6):1550-1
77. Siebenhaar F, Kuhn W, Zuberbier T, et al. Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. J Allergy Clin Immunol 2007;120(1):213-15
78. Buyukozturk S, Gelincik A, Demirturk M, et al. Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: a real life survey. J Dermatol 2012;39(5):439-42
79. Nadeau KC, Schneider LC, Hoyte L, et al. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. J Allergy Clin Immunol 2011;127(6):1622-4
80. Rafi A, Do LT, Katz R, et al. Effects of omalizumab in patients with food allergy. Allergy Asthma Proc 2010;31(1):76-83
81. Bedoret D, Singh AK, Shaw V, et al. Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab. Mucosal Immunol 2012;5(3):267-76
82. Leung DY, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003;348(11):986-93
83. Sampson HA, Leung DY, Burks AW, et al. A Phase II, randomized, doubleblind, parallelgroup, placebocontrolled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2011;127(5):1309-10 e1
84. Savage JH, Courneya JP, Sterba PM, et al. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol 2012;130(5):1123-9 e2
85. Agarwal S, Gawkrodger DJ. Latex allergy: a health care problem of epidemic proportions. Eur J Dermatol 2002;12(4):311-15
86. Sussman GL, Beezhold DH, Kurup VP. Allergens and natural rubber proteins. J Allergy Clin Immunol 2002;110(2 Suppl):S33-9
87. Leynadier F, Doudou O, Gaouar H, et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 2004;113(2):360-1
88. Stone KD, Prussin C. Immunomodulatory therapy of eosinophil-associated gastrointestinal diseases. Clin Exp Allergy 2008;38(12):1858-65
89. Foroughi S, Foster B, Kim N, et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol 2007;120(3):594-601
90. Rocha R, Vitor AB, Trindade E, et al. Omalizumab in the treatment of eosinophilic esophagitis and food allergy. Eur J Pediatr 2011
91. Williams PB, Sheppard JD Jr. Omalizumab: a future innovation for treatment of severe ocular allergy? Expert Opin Biol Ther 2005;5(12):1603-9
92. van der Ent CK, Hoekstra H, Rijkers GT. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007;62(3):276-7
93. Zirbes JM, Milla CE. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 2008;43(6):607-10
94. Lebecque P, Leonard A, Pilette C. Omalizumab for treatment of ABPA exacerbations in CF patients. Pediatr Pulmonol 2009;44(5):516
95. Lebecque P, Leonard A, Argaz M, et al. Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. BMJ Case Rep 2009; doi:10.1136/bcr.07.2008.0379
96. Kanu A, Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol 2008;43(12):1249-51
97. Randhawa I, Chin T, Nussbaum E. Resolution of corticosteroid-induced diabetes in allergic bronchopulmonary aspergillosis with omalizumab therapy: a novel approach. J Asthma 2009;46(5):445-7
98. Lin RY, Sethi S, Bhargave GA. Measured immunoglobulin E in allergic bronchopulmonary aspergillosis treated with omalizumab. J Asthma 2010;47(8):942-5
99. Collins J, Devos G, Hudes G, et al. Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab. J Asthma Allergy 2012;5:65-70
100. Sastre I, Blanco J, Mata H, et al. A case of allergic bronchopulmonary aspergillosis treated with omalizumab. J Investig Allergol Clin Immunol 2012;22(2):145-7
101. Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, et al. Administration of anti-IgE to a Churg-Strauss syndrome patient. Int Arch Allergy Immunol 2007;144(2):155-8
102. Pabst S, Tiyerili V, Grohe C. Apparent response to anti-IgE therapy in two patients with refractory "forme fruste" of Churg-Strauss syndrome. Thorax 2008;63(8):747-8
103. Cazzola M, Mura M, Segreti A, et al. Eosinophilic pneumonia in an asthmatic patient treated with omalizumab therapy: forme-fruste of Churg-Strauss syndrome? Allergy 2009;64(9):1389-90
104. Wechsler ME, Wong DA, Miller MK, et al. Churg-strauss syndrome in patients treated with omalizumab. Chest 2009;136(2):507-18
105. Jones JD, Marney SR Jr, Fahrenholz JM. Idiopathic anaphylaxis successfully treated with omalizumab. Ann Allergy Asthma Immunol 2008;101(5):550-1
106. Warrier P, Casale TB. Omalizumab in idiopathic anaphylaxis. Ann Allergy Asthma Immunol 2009;102(3):257-8
107. Pitt TJ, Cisneros N, Kalicinsky C, et al. Successful treatment of idiopathic anaphylaxis in an adolescent. J Allergy Clin Immunol 2010;126(2):415-16; author reply 6
108. Demirturk M, Gelincik A, Colakoglu B, et al. Promising option in the prevention of idiopathic anaphylaxis: omalizumab. J Dermatol 2012;39(6):552-4
109. Douglass JA, Carroll K, Voskamp A, et al. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy 2010;65(7):926-7
110. Bobolea I, Barranco P, Fiandor A, et al. Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease. J Investig Allergol Clin Immunol 2010;20(5):448-9
111. Ferguson BJ, Otto BA, Pant H. When surgery, antibiotics, and steroids fail to resolve chronic rhinosinusitis. Immunol Allergy Clin North Am 2009;29(4):719-32
112. Bard S, Paravisini A, Aviles-Izquierdo JA, et al. Eczematous dermatitis in the setting of hyper-IgE syndrome successfully treated with omalizumab. Arch Dermatol 2008;144(12):1662-3
113. Lee J, Doggweiler-Wiygul R, Kim S, et al. Is interstitial cystitis an allergic disorder?: a case of interstitial cystitis treated successfully with anti-IgE. Int J Urol 2006;13(5):631-4
114. Pinto JM, Mehta N, DiTineo M, et al. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 2010;48(3):318-24
115. Chularojanamontri L, Wimoolchart S, Tuchinda P, et al. Role of omalizumab in a patient with hyper-IgE syndrome and review dermatologic manifestations. Asian Pac J Allergy Immunol 2009;27(4):233-6
116. Aksu K, Kurt E. Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory disease. Allergol Immunopathol (Madr) 2012; http://dx.doi.org/10.1016/j. aller.2012.02.005
117. Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria. N Engl J Med 2013;368(10):924-35
118. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108(2):184-190
119. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001;108(2):E36
120. Milgrom H, Fick RB, Jr., Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb- E25 Study Group. N Engl J Med 1999;341(26):1966-73
121. Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-tosevere) allergic asthma. Allergy 2004;59(7):701-8
122. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18(2):254-61